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Activating mutations in NRAS and BRAF are found frequently in cutaneous melanomas. Because concurrent
mutations of both BRAF and RAS are extremely rare, it is thought that transformation by RAS and BRAF occurs
through a common mechanism. Also, there is evidence for a relationship of synthetic lethality between NRAS and
BRAF oncogenes that leads to selection against cells with a hyperactive mitogen-activated protein kinase (MAPK)
pathway. However, it is not known whether the hyperactivation of the MAPK pathway by overexpression of either
oncogene alone could also inhibit melanoma tumorigenesis. Here, we show that in melanoma cells with oncogenic
BRAF (mBRAF), high levels of mBRAF induce hyperactivation of ERK and senescence-like phenotype and trigger
autophagy by inhibiting the mammalian target of rapamycin complex signaling. Growth inhibition and cell death
caused by high mBRAF levels are partially rescued by downregulation of BRAF protein or inhibition of autophagy,
but not by inhibition of the MAPK or apoptotic pathways. In nude mice, growth of mBRAF-overexpressing tumors is
inhibited. Quantitative immunohistochemical analysis of human melanomas and cell lines showed a significant
positive correlation between the levels of BRAF protein and autophagy marker light chain 3. Our data suggest that
high oncogenic BRAF levels trigger autophagy, which may have a role in melanoma tumor progression.
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INTRODUCTION
Activating mutations in RAS and the RAS effector BRAF,
which activate the mitogen-activated protein kinase (MAPK)
signaling pathway, are found in a majority of melanomas
(Demunter et al., 2001; Davies et al., 2002; Solit et al., 2006).
As the concurrent mutations of both BRAF and RAS are
extremely rare, it is thought that transformation by RAS and
BRAF occurs through a common mechanism involving the
MEK-ERK signaling cascade (Sensi et al., 2006). However, the
specific role of oncogenic BRAF in melanoma remains to be
understood (Karreth et al., 2009). For example, it has been
shown that BRAF is not required for MAPK activation in
RAS-transformed melanocytes (Wellbrock et al., 2004; Dumaz
et al., 2006). Although melanoma cell lines with activating
mutation in BRAF are more sensitive in vitro to MEK
inhibition than RAS mutant cell lines (Solit et al., 2006),
there was no correlation in vivo between the activation status
of BRAF and the proportion of phosphor-ERK-positive cells
or clinical course of the disease (Uribe et al., 2006).
Moreover, sorafenib, a multikinase inhibitor that also inhibits
BRAF kinase, has little or no antitumor activity in advanced
melanoma patients as a single agent (Eisen et al., 2006).
Paradoxically, hyperactivation of RAS or BRAF and high
levels of MAPK activities are also known to induce
senescence and inhibit cell proliferation (Serrano et al.,
1997; Braig and Schmitt, 2006). In both the in vitro and
in vivo model systems, activated BRAF has been shown to
induce only nonmalignant changes in melanocytes, consistent
with the hypothesis that BRAF induces a biphasic cellular
response, i.e., an initial proliferative burst followed by
senescence (Michaloglou et al., 2005; Dankort et al., 2007).
Thus, a majority of benign melanocytic nevi, which harbor
activating BRAF mutations, also exhibit hallmarks of senes-
cence (Michaloglou et al., 2005), suggesting that there may be
an upper threshold for MAPK activation above which
senescence is reactivated even in tumor cells. Thus, in human
melanoma cells that carry mutant NRASQ61R, expression of
BRAFV600E activates senescence, suggesting a relationship of
synthetic lethality between the NRAS and BRAF oncogenes
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that results in selection against cells with a hyperactive MAPK
pathway (Petti et al., 2006). Although it is known that
additional genetic changes are required for cellular escape
from BRAF-induced senescence (Michaloglou et al., 2005;
Patton et al., 2005; Dankort et al., 2009) and that activated
BRAF is required for tumor growth and maintenance (Hoeflich
et al., 2006), the relationship between the BRAF oncogene
dosage and melanoma tumor progression and its responsive-
ness to treatment with BRAF kinase inhibitors is not known.
Here, we show that high mBRAF expression not only
inhibits cell growth and triggers autophagy by inhibiting
mTOR signaling, but also inhibits tumor growth in vivo by
hemorrhagic necrosis. In human melanoma cell lines and
tumor tissues, expression levels of BRAF protein showed a
positive correlation with a marker of autophagy. These
findings suggest a role for BRAF dosage-dependent autophagy
in melanoma development and progression.
RESULTS
Overexpression of BRAFV600E inhibits growth of melanoma cells
A survey of a representative panel of primary and metastatic
human melanoma cell lines with wild-type or mutant
RAS or BRAF alleles showed that although melanoma cell
lines have nearly three- to fivefold more BRAF protein and
RAF kinase activity compared with cultured melanocytes,
there was no clear correlation between the BRAF mutation
status or BRAF expression levels and the RAF kinase
activity or pERK1/2 (see Supplementary Data, Supplementary
Figure S1 online). For example, metastatic melanoma cell
lines 451Lu harboring the mutant BRAF allele and SK-MEL-2
carrying a mutation in RAS have similar levels of BRAF
protein, RAF kinase activity, and pERK. To investigate the
effect of hyperstimulation of the MAPK pathway in melanoma
cells, we transfected oncogenic BRAFV600E (mBRAF) expression
plasmid into melanoma cell lines 451Lu and SK-MEL-2
and generated stable cell lines expressing nearly twofold
more BRAF protein compared with vector-transfected cells
(Figure 1a, left and Figure 2a). The two high-mBRAF 451Lu
stable clones, mBRAF2 and mBRAF3, isolated from two
separate transfections, showed a decreased rate of prolifera-
tion despite having increased pERK levels (Figure 1b, left;
Supplementary Figure S2a and S2b). Similarly, in a stable
clone of 451Lu transfected with an inducible expression
plasmid ER-BRAFV600E, a dose-dependent inhibition of
growth was observed when mBRAF expression was increased
(up toB20%) by treatment with tamoxifen (Figure 1a and b,
right, and Supplementary Figure S2c). Tamoxifen treatment
had no effect on the growth of the parental 451Lu cells.
In a clonogenic survival assay, 451Lu-mBRAF clones
produced 50% fewer colonies than vector control cells
(Figure 1c). To rule out the possibility that the stable
clones represent clonally expanded, rare, and slow-growing
G418-resistant variants of parental 451Lu melanoma cells,
we studied the effect of transient overexpression of mBRAF in
451Lu cells as well as WM35 (a primary melanoma cell line
that carries the mutant BRAF allele). Both WM35 and 451Lu
cells showed significant growth inhibition similar to the stable
clones (Supplementary Figure S3a). Transient expression of
mBRAF in additional melanoma cells lines (SK-MEL-28,
Hs294T, and WM115) also resulted in variable growth
inhibition (Supplementary Figure S4), confirming that high
mBRAF levels inhibit melanoma cell proliferation. Interestingly,
overexpression of BRAF and high pERK levels did not inhibit
the growth of melanoma cell line SK-MEL-2, which carries
wild-type BRAF and mutant RAS gene (Figure 2a–c), suggesting
that hyperactivation of the oncogenic BRAF and MAPK pathway
in melanoma cells with activated BRAF, but not activated RAS,
results in growth inhibition.
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Figure 1. Overexpression of oncogenic BRAF inhibits growth. (a) 451Lu metastatic melanoma cells harboring BRAF V600E mutation were transfected with
empty vector (pMCEFplink) or mBRAF (pMCEFBRAFV600E) expression plasmid using Nucleofector (Amaxa) and two G418-resistant clones were selected
from two separate transfections. Puromycin-resistant stable clones from empty vector or pLXSP3-G BRAFVE:ERT2 plasmid transfections of 451Lu were generated.
Cell lysates were analyzed by western blots using the anti-BRAF antibody. (Numbers below the bands indicate fold increase in BRAF protein.) Actin shows equal
loading. (b) MTT assay for cell proliferation. Left: 451Lu-mBRAF clones; right: 4-OHT (4-hydroxytamoxifen)-inducible ER-mBRAF clone. Representative data
from three independent experiments are shown (*Po0.001). (c) Colony-forming ability of 451Lu control and mBRAF clones. Cells (5000 per well) were plated
in triplicate, and 2 weeks later crystal violet-stained colonies were counted. Representative data from three independent experiments are shown (*Po0.001).
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Hyperactivation of BRAF induces senescence-like features but
not cell cycle arrest and apoptosis
As activated BRAF induces senescence in melanocytes, we
asked whether high mBRAF levels can reactivate senescence
in melanoma cells. We used senescence-associated-b-galac-
tosidase, p16 expression, and acetylated histone H3
(AcH3K9) as markers of senescence. In 451Lu-mBRAF, we
observed a threefold increase in senescence-associated-b-
galactosidase stained-positive cells (Figure 3a), upregulation
of p16 protein and a decrease in acetylated histone H3
(Figure 3b). Similar increase in senescence-associated-b-
galactosidase-positive cells was seen in SK-MEL-2 mBRAF
stable clone, and also in WM35 and 451Lu cells transiently
transfected with mBRAF (Supplementary Figure S3b). To-
gether, these data suggest that overexpression of mBRAF
(re)activates senescence in both mutant RAS and mutant
BRAF melanoma cells, whereas high BRAF levels only inhibit
the growth of cells expressing endogenous BRAFV600E.
To understand the mechanisms of growth inhibition by
high mBRAF, we evaluated cell cycle distribution and TUNEL
staining. In 451Lu-mBRAF cells, although there seems to be a
small increase in the S-phase, there was no change in the
proportion of cells in the G1 or G2/M phases of the cell cycle
or the number of TUNEL-positive cells between vector and
451Lu-mBRAF clones (Figure 3c). Addition of 5 mM fmk-
ZVAD, a pan-caspase inhibitor, to the culture medium did
not rescue growth of 451Lu-mBRAF clones (Figure 3d).
Treatment of vector control 451Lu cells with the same
concentration of fmk-ZVAD modestly increased their survival
(Figure 3d) and was sufficient to rescue, partially but
significantly, tumor necrosis factor-a-induced apoptosis
(Supplementary Figure S5). These data show that cell cycle
arrest and apoptosis are not primary mechanisms of growth
inhibition caused by high mBRAF levels.
High level of oncogenic BRAF induces autophagy
We asked whether autophagy, an alternative form of cell
death, could account for the growth inhibition caused by
mBRAF overexpression. First, immunofluorescence staining
for the autophagy marker microtubule-associated protein
light chain 3 (LC3, a mammalian homolog of Atg8, a yeast
protein involved in autophagy) showed punctate staining of
LC3-positive autophagic vesicles in mBRAF3 (Figure 4a, top).
The specificity of LC3 staining was verified by a similar
pattern of accumulation of transfected green fluorescent
protein (GFP)–LC3 fusion protein (Kabeya et al., 2000) in
vesicles in 451Lu-mBRAF2 cells but not in control cells.
Treatment with brefeldin A, an inducer endoplasmic stress
and autophagy (Turcotte et al., 2008), also produced a similar
pattern of GFP–LC3 accumulation in vector control 451Lu
cells (Figure 4a, lower) showing the prevalence of autopha-
gosomes in mBRAF cells. Biochemically, the autophago-
some-associated lipidated form of LC3 (LC3-II) can be
distinguished from free LC3 (LC3-I) by immunoblotting
(Kabeya et al., 2000). Consistent with the morphological
findings, a higher amount of lipidated LC3-II was seen in
451Lu-mBRAF clones (Figure 4a). Staining with the fluor-
escent dye monodansyl cadavarine, which labels large acidic
autophagosome lysosomes (Supplementary Figure S6a), and
transmission electron microscopy that showed characteristic
double-membrane autophagic vesicles (Figure 4a) and
numerous vacuoles (Supplementary Figure S6b) supported
our data on activation of autophagy in melanoma cells
overexpressing mBRAF.
Activation of autophagy in 451Lu-mBRAF cells raised the
possibility that autophagic cell death might contribute to
growth inhibition by high mBRAF. To test this, we treated
control and mBRAF cells with 3-methyladenine (3-MA), an
inhibitor of autophagy (Petiot et al., 2000), and evaluated the
proportion of dead cells. In untreated 451Lu-mBRAF clones,
there were 2–3 times more dead cells compared with vector-
transfected 451Lu cells. Treatment with 3-MA for 48 hours
significantly reduced the number of dead cells in the mBRAF
clone, whereas 3-MA treatment had no effect on control cells
(Figure 4d). A reduction in the amount of lipidated LC3-II in
3-MA-treated cells verified inhibition of autophagy by 3-MA
(Supplementary Figure S6c). Conversely, the MTT assay
showed that treatment with 3-MA resulted in a small, but
significant, increase in growth of mBRAF cells (Supplemen-
tary Figure S6d).
As mammalian target of rapamycin (mTOR) is known to
regulate autophagy, we tested whether hyperactivation of
BRAF modulates mTOR activity. Western blot analysis of
components of the mTOR complexes (Figure 4e) showed an
increase in phosphorylation of mTOR at Ser2481 and an
increase in Rictor, which are associated with the rapamycin-
insensitive mammalian target of rapamycin complex-2
(mTORC2). There was no marked change in phosphorylation
at Ser2448 and the expression of Raptor, which, however, are
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Figure 2. RAS mutant, BRAF wild-type SK-MEL-2 cells are refractory to
oncogenic BRAF. (a) Western blot analysis vector control and stable
mBRAF expressing SK-MEL-2 metastatic melanoma cells. Actin shows equal
loading. (b) Cells (1 105) were plated in a six-well plate and growth was
measured by crystal violet assay. (c) Clonogenicity of control and mBRAF SK-
MEL-2 cells. Crystal violet-stained colonies were counted and the number
of colonies is shown.
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associated with mTORC1 that negatively regulates autophagy
(Copp et al., 2009). Treatment of 451Lu vector control cells
with autophagy-inducer brefeldin A also caused a similar
increase in Rictor (lane 4, Figure 4e). Decreased signaling by
mTORC1 in mBRAF cells is also indicated by reduced
phospho-4E-BP1 (the translational repressor of eukaryotic
elongation factor-binding protein) (Figure 4f). Similarly,
phosphorylation of Akt at Thr308 and tuberin (TSC2) at
Thr1462, both components upstream of mTORC1, is also
decreased in mBRAF cells (Figure 4f). These data suggest that
hyperactivation of BRAF inhibits Akt-mTORC1 signaling and
thereby attenuates the negative regulation of autophagy by
mTORC1. Thus, high levels of oncogenic BRAF appear to
inhibit growth and induce autophagy-associated cell death by
modulating the mTOR signaling pathway that is reported to
be activated in the majority of melanomas (Karbowniczek
et al., 2009).
To test whether pharmacological inhibition of mTOR by
rapamycin also induces autophagy and inhibits melanoma
cell growth, we treated 451Lu cells with rapamycin
(0.1–2 mM) and measured cell proliferation (by MTT assay)
and induction of autophagy (by GFP-LC3 staining). As shown
in Supplementary Figure S7, treatment with 2mM rapamycin
caused significant growth inhibition and vesicular accumula-
tion of GFP-LC3, showing that inhibition of the rapamycin-
sensitive mTORC1 leads to induction of autophagy in 451Lu
melanoma cells.
Downregulation of BRAF inhibits autophagy
Next, we asked whether autophagy-associated growth
inhibition by high mBRAF can be reversed by reducing BRAF
levels. For this, we used BRAF small hairpin RNA (shRNA)
lentiviral transduction followed by selection in puromycin.
First, we titrated the virus and used a titer to achieve B20%
decrease in BRAF protein levels (Figure 5a). This level of
BRAF knockdown in control 451Lu cells resulted in a small
but significant decrease in growth. In contrast, a similar
knockdown of BRAF in 451Lu-mBRAF cells resulted in a
significant increase in growth (Figure 5b), suggesting that a
high level of activated BRAF is required for growth
suppression. Knockdown of BRAF also decreased senescence
as indicated by the p16 levels (Figure 5c).
Infection with higher titers of BRAF shRNA lentivirus,
which caused a further decrease (40–50%) in BRAF levels,
significantly inhibited proliferation of both control and
451Lu-mBRAF cells (Supplementary Figure S8a and b), as
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Figure 3. Hyperactivation of mBRAF induces senescence but not apoptosis in melanoma cells. (a) Cells (5,000 per well) were plated in triplicate and stained
to detect senescence-associated-b-galactosidase (SA-b-gal) (insets), and percent SA-b-gal-positive cells were counted. Representative data from three
independent experiments are shown (*Po0.001). (Bar¼ 4mm). (b) Immunoblot analysis of p16INK4A and acetylated H3K9. Actin was used as a loading control.
(c) Expression of mBRAF does not inhibit cell cycle. 451Lu vector and mBRAF-expressing cells were stained with propidium iodide and analyzed by flow
cytometry for cell cycle distribution (upper) and TUNEL-positive cells (lower). (d) Inhibition of apoptosis does not rescue the growth of high mBRAF cells.
Control and 451Lu-mBRAF cells were treated with pan-caspase inhibitor fmk-ZVAD, and cell survival was measured by MTT assay. Representative data from
three independent experiments are shown.
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expected, showing that a threshold level of BRAF is required
for survival of melanoma cells, whereas high BRAF levels are
growth inhibitory.
Next, we tested whether sustained high activation of BRAF
downstream effector MEK is also required for growth
suppression by high mBRAF. We treated cells with MEK
inhibitor U0126 at a concentration (0.5 mM) that inhibits the
growth of control 451Lu cells by 30% after a 7-day treatment.
A similar treatment, however, did not significantly affect the
survival or growth of 451Lu-mBRAF cells (Figure 5d).
Western blot analysis did not reveal a marked difference in
the degree of inhibition of ERK1/2 phosphorylation by U0126
in vector control compared with mBRAF cells (Supplemen-
tary Figure S9). Together, these data suggest that a high level
of oncogenic BRAF, but not sustained activation of the MEK-
ERK pathway, suppresses melanoma cell growth.
BRAF-induced autophagy and melanoma progression in vivo
To investigate the relevance of autophagy triggered by high
mBRAF to melanoma growth in vivo, we used the mouse
xenograft model. We injected vector control and 451Lu-
mBRAF cells (1 106) into flanks of 4- to 6-week-old athymic
nude mice and measured the kinetics of tumor growth. As
shown in Figure 6a, mBRAF tumors grew significantly slower,
and by day 40, the tumors were up to 45% smaller than the
vector control tumors (two-tailed Student’s t-test, P¼0.03).
Kaplan–Meier analysis (percent animals surviving with a
tumor volume of X1000mm3) showed significant difference
in survival of control and 451Lu-BRAF-injected mice (Figure
6a; P¼0.0035 for mBRAF2 and P¼ 0.0003 for mBRAF3).
Interestingly, after 3–4 weeks of growth, most mBRAF
tumors appeared red (hemorrhagic), became progressively
necrotic, and showed a concave surface contour (Figure 6b
and Supplementary Figure S10). At day 60, when all mice
were killed, 7 of 10 mBRAF2 and 8 of 9 mBRAF3 mice
showed varying levels of necrosis as scored by the surface
diameter of the tumor-showing necrosis (Carswell et al., 1975),
whereas none (0/9) of the vector control tumor-bearing mice
showed necrosis (Figure 6b and table below). Histochemical
staining of the tumor sections showed robust angiotropic
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Figure 4. High level of oncogenic BRAF activates autophagy in melanoma cells. (a) Immunofluorescence staining of autophagic marker MAP1LC3 in 451Lu-
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growth of cells in control tumors, whereas considerable
engorgement and congestion of blood vessels accompanied
by hemorrhagic necrosis could be seen in mBRAF tumors
with ghost cells (cell shadows) making up the bulk of the
tumor (Figure 6c). Immunohistochemical analysis of LC3
showed higher expression in mBRAF tumor cells compared
with vector control tumors (Figure 6c). Electron microscopy
of residual mBRAF tumors showed characteristic ultrastruc-
tural features of necrosis (Figure 6d), such as irregularly
condensed chromatin, breakdown of plasma membrane and
organelles, and clear cytoplasm with vacuoles (Romanko
et al., 2004). These data suggest that activation of mBRAF
induces autophagy and inhibits tumor growth in this in vivo
mouse xenograft model.
To test whether in human melanomas expression levels of
BRAF correlate with expression levels of autophagy marker
LC3, we performed automated quantitative immunohisto-
chemistry analysis (AQUA) using a tissue array consisting of
primary (n¼16) lymph node (n¼ 12) and distant metastases
of melanoma (n¼ 12), and a representative set of human
cutaneous melanoma cell lines (n¼5). The range of AQUA
signal intensities for BRAF and LC3 are shown in Table 1 and
representative staining of two primary melanoma tumor cores
is shown in Figure 7. Core 36 represents a tumor with low
BRAF (AQUA score: 12.96) and LC3 (37.87) expression, and
Core 39 represents a tumor with high BRAF (35.86) and LC3
(51.91) expression. Spearman’s correlation analysis of in-
tensity values of the three markers showed that BRAF and LC3
are significantly correlated among all melanoma samples
(r¼0.591; P¼ 0.002). In contrast, expression of MAP2, a
neuronal differentiation marker that we previously showed to
be expressed in cutaneous melanomas (Fang et al., 2001),
showed no correlation with BRAF levels (Table 1). These data
suggest that high levels of oncogenic BRAF correlate with
expression of autophagic marker in human melanoma,
implicating BRAF dosage-dependent autophagy as a deter-
minant of melanoma tumor progression.
DISCUSSION
In this study, we show that overexpression of BRAFV600E in
melanoma cells induces not only senescence-like features but
also autophagy-associated growth inhibition both in vitro and
in vivo. Oncogene-induced senescence and growth arrest
in vivo are considered barriers to tumorigenesis (Prieur and
Peeper, 2008) and the molecular details of oncogene-
induced senescence and the mechanisms of its evasion have
been extensively investigated (Wajapeyee et al., 2008). The
effect of different oncogene expression levels on cell fate has
been investigated (Chen et al., 2008). Using a regulated
expression model system, it was proposed that a multistep
Ras tumorigenesis model requires at least three distinct
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Figure 5. High levels of mBRAF are required for growth inhibition. (a) Partial
knockdown of BRAF by shRNA lentivirus. Vector control and mBRAF cells
were infected with (equal MOI) scrambled (control) and BRAF shRNA
lentivirus. Transduced cells were selected by treating the cells with 1 mgml1
of puromycin for 10 days. Western blot analysis shows total BRAF protein
levels in control and mBRAF cells. Actin control for equal protein loading is
shown. (b) Partial knockdown of BRAF restores growth of 451Lu-mBRAF cells.
BRAF shRNA-transduced, puromycin-selected cells were plated in a 96-well
plate, and the cell growth was measured after 1 and 3 days using MTT dye.
Representative data of three independent experiments are shown (N¼ 5,
*Po0.05; **Po 0.001). (c) Partial knockdown of BRAF in mBRAF3 by shRNA
plasmid (BRAF9 and BRAF10) transfection. Western blot analysis of total
BRAF and p16 in control and BRAF shRNA-transduced cells. Actin control for
equal protein loading is shown. (d) Inhibition MAPK signaling does not rescue
growth of 451Lu-mBRAF cells. Vector control and 451Lu-mBRAF cells were
treated with MEK inhibitor (0.5–10 mM, U0126) and growth was measured by
MTT assay. Representative data of three experiments are shown.
Figure 6. Overexpression of oncogenic BRAF inhibits tumor growth and correlates with expression of autophagy marker in vivo. 451Lu vector control and
mBRAF cells (1 106) were injected subcutaneously in the right flank of nu/nu athymic mice. Tumors were measured twice a week for 6 weeks in control
(n¼9), mBRAF2 (n¼ 10), and mBRAF3 (n¼ 9) mice. (a) Left: Kinetics of tumor growth shown as mean (±SEM) tumor volume (mm3) (Two-tailed Student’s t-test
*P¼0.03). In all three groups, mice with the largest and smallest tumor volume were removed from the analysis. Right: Kaplan–Meier survival analysis. Percent
mice that reached tumor size of 1000mm3 were plotted against time (*P¼ 0.0035 and **P¼ 0.0003). (b) Necrosis of mBRAF tumors. By 3–4 weeks, most 451Lu-
mBRAF tumors were red (hemorrhagic) in color and became progressively necrotic (black) with a recessed or concave surface contour. Necrosis was graded (0,
þ1 to þ3) as the surface area of the tumor showing black color, and the numbers in the table represent the number of animals with particular necrosis score at
day 60. (c) Histology and expression of autophagy marker LC3 in vivo. Formalin-fixed 451Lu vector control and mBRAF tumors were sectioned and stained with
hematoxylin and eosin (H&E) (bars¼ 4mm; top and middle panels) and immunostained for LC3 (bar¼ 50mm; bottom panel). Representative H&E and
immunostained sections of a control and mBRAF tumors are shown. Arrows indicate necrosis and arrowheads show red hemorrhagic areas. (d) Ultrastructure of
451Lu vector control and mBRAF tumors show necrotic features in mBRAF tumors. Excised tumor tissues were fixed and processed for transmission electron
microscopy. Upper panels: low magnification (bar¼5 and 10mm for vector and mBRAF, respectively); lower panels: higher magnification (bar¼2 mm).
N: nuclei; *: vacuoles, and arrowheads: plasma membrane.
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oncogenic events––low level of oncogenic activation that
stimulates proliferation, spontaneous upregulation of acti-
vated Ras levels that induce senescence and, finally, evasion
of senescence and tumor progression (Sarkisian et al., 2007).
Distinct threshold levels of Myc in vivo also seem to
determine its biological output, suggesting that low-level
1200
1000
800
600
400
200
0
Vector
mBRAF clone 3
Pe
rc
e
n
t s
ur
vi
va
l
Tu
m
o
r 
vo
lu
m
e 
(m
m3
)
100
80
60
40
20
0
mBRAF clone 2
Vector
mBRAF clone 3
mBRAF clone 2
mBRAF clone 3
mBRAF clone 2
mBRAF
Days
Hemorrhagic
Necrosis score
Group –
9
3 3
2 2
2
41
Hemorrhagic
0 0 0 0
1 1
0
Vector
Vector
LC
3
H
&E
H
&E
mBRAFVector
– +
+
++
++
+++
+++
P=0.03
10 15 20 25 30 35 40 45
Time
0 10 20 30 40 50 60 70
*
**
www.jidonline.org 1663
N Maddodi et al.
Induction of Autophagy by Oncogenic BRAF
deregulated Myc may be a more efficient initiator of
oncogenesis than overexpressed Myc (Murphy et al., 2008).
Similarly, an in vivo mouse model of BRAFV600E expression
regulated by its own promoter also suggested that the distinct
biological outcomes might be due to differences in the level
of oncogene expression or activation (Dankort et al., 2007).
Our data show that overexpression of oncogenic BRAF even
in highly aggressive metastatic melanoma cells harboring
endogenous activated BRAF can alter their growth.
The differences in biological responses to oncogene
dosage levels are highlighted by our observation that even
among melanoma cell lines, the effects of overexpression of
BRAFV600E are dependent on the endogenous activated
oncogene, RAS versus. BRAF. Thus, although metastatic
melanoma SK-MEL-2 cells that carry a mutation in RAS, but
not in BRAF, are also susceptible to induction of senescence
by mBRAF, they do not undergo proliferative arrest. This is in
contrast to the observations that expression of activated
N-RAS in metastatic melanoma cells harboring BRAF
mutation causes growth inhibition because of cell cycle
arrest in the G0/G1 phase and activation of senescence-
associated markers (Petti et al., 2006). Although the mutually
exclusive occurrence of mutations in RAS and BRAF genes in
melanoma is thought to indicate a common mechanism of
action involving the downstream MEK–ERK pathway, BRAF
appears to be dispensable for the RAS-activated MAPK
pathway. In RAS-transformed melanocytes and melanoma
cells harboring oncogenic RAS, depletion of BRAF did not
block MEK–ERK signaling or cell cycle progression (Well-
brock et al., 2004). In addition, although overexpression of
oncogenic BRAF induces senescence, it has been suggested
that it is the inactivation by the inhibitory NF1 feedback loop
rather than hyperactivation of the RAS pathway that acts a
senescence trigger (Courtois-Cox et al., 2006). Thus, acti-
vated RAS and BRAF appear to activate common as well as
distinct signaling mechanisms.
The observation that a pan-caspase inhibitor failed to
rescue proliferation of mBRAF clones, together with the
absence of cell cycle arrest and TUNEL-positive cells,
prompted us to explore alternative cell death mechanisms.
Autophagy is activated as a cell survival mechanism in
response to nutrient or growth factor starvation. However,
prolonged or extensive autophagy is known to contribute to
cell death (Qu et al., 2003; Galluzzi et al., 2008). Although it
has been documented that several oncogenes inhibit
autophagy and tumor suppressors induce autophagy, the role
of autophagy in tumor development and progression remains
controversial (Maiuri et al., 2008). Induction of autophagy by
high BRAFV600E may seem contradictory to the proposed role
of oncogenes, but it is consistent with the complex relation-
ship between autophagy and tumorigenesis (Maiuri et al.,
2008). In NIH3T3 cells, overexpression of mutant H-Ras/
Val12 has been shown to have a role in the regulation of
nutrient starvation-induced autophagy through MAPK-inde-
pendent pathways and through the class I PI3 kinase signaling
pathway (Furuta et al., 2004). However, it must be noted that
in colon cancer HT29 cells, overexpression of Ras/Val12
stimulates, rather than inhibits, autophagy (Pattingre et al.,
2003). Thus, regulation of autophagy by oncogene over-
expression appears to be cell type-specific. We show that
high levels of BRAFV600E not only induce autophagy-associated
Table 1. Automated quantitative
immunohistochemistry analysis (AQUA) of human
melanoma tissue array
BRAF LC3 MAP2
n 33 26 32
Minimum 12.96 19.32 23.89
Maximum 77.51 154.2 165.6
Mean 22.39 52.48 70.11
First quartile 17.3 26.62 43.52
Third quartile 23.36 60.67 85.64
A melanoma trial tissues array (obtained from the National Cancer
Institute, NIH, USA) containing primary (n=16), lymph node (n=12), and
distant melanoma (n=12) and melanoma cell lines (n=5) was used for
immunohistochemistry staining, and staining intensity data was acquired
using AQUA. Tissues were masked with S100 antibody and stained with
BRAF and LC3 and MAP2 antibody, and DAPI was used to stain the
nuclei. Table shows the AQUA values of the tissues stained with BRAF,
LC3, and MAP2.
Co
re
 3
9
Co
re
 3
9
Co
re
 3
6
Co
re
 3
6
LC3 S100
BRAF S100 DAPI
DAPI
Figure 7. Automated quantitative analysis (AQUA) of human melanoma
tissue array. A melanoma trial tissues array (obtained from the National
Cancer Institute, NIH, USA) was used for immunofluorescent staining. The
staining intensity was analyzed using AQUA. Melanoma was masked with
S100 antibody and visualized with Alexa Fluor 555 (green) tagged secondary
antibodies. BRAF and LC3 were stained and visualized with Alexa Fluor 647
(red) tagged secondary antibodies. 4,6-Diamidino-2-phenylindole (DAPI) was
used to stain and visualize the nuclei (blue). Representative images of primary
melanoma tissues stained with BRAF (upper), LC3 (lower), S100, and DAPI
are shown (bar¼200 pi).
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growth inhibition but also correlate with higher expression
of autophagy marker LC3 in human melanoma tumors,
suggesting a tumor-suppressive role for BRAF-induced
autophagy in melanoma.
Autophagy is negatively regulated by mTOR signaling
(Lum et al., 2005). There are two distinct mTOR complexes,
mTORC1 and mTORC2, that consist of distinct mTOR-
binding proteins and also have different substrate specificities
(Corradetti and Guan, 2006). We show that overexpression of
mBRAF can downregulate mTOR signaling, specifically of
mTORC1, which negatively regulates autophagy. On the
basis of the recently published observations and our data that
show an increase in the phosphorylation of mTOR on
Ser2481 and an increase in Rictor, which are associated
with mTORC2 (Copp et al., 2009), we suggest that cross talk
between BRAF and mTOR signaling has a role in determining
the fates of neoplastic melanocytes. This is supported by the
observation that BRAF kinase activity is inhibited by Ras
homolog enriched in the brain (Rheb) that binds and
regulates mTOR kinase signaling, which is reported to be
upregulated in the majority of melanomas (Karbowniczek
et al., 2004, 2009; Long et al., 2005). Recently, GOLPH3, a
Golgi-located protein that modulates mTOR signaling and
rapamycin sensitivity in cancer, including melanoma, has
been shown to be a previously unknown oncogene support-
ing a role for mTOR signaling in melanoma cell survival
(Scott et al., 2009).
Although it has been proposed that the inhibition of
autophagy could be used as the treatment of cancer, the role
of autophagy in tumor progression and the benefit of
induction of autophagy in cancer therapy remain to be
settled (Høyer-Hansen and Ja¨a¨ttela¨, 2008). Our data on
oncogenic BRAF dosage-dependent induction of autophagy
and growth inhibition in both primary and metastatic cells
raises the possibility that in melanomas with activated BRAF,
autophagy can serve not only as a prognostic indicator but
also as an alternative cell death pathway that can be
exploited for treatment.
MATERIALS AND METHODS
Cell culture
Melanoma cell lines WM115, SK-MEL-2, 28, 31, and human
embryonal carcinoma cell lines, NT2/D1 and HEK293T, were
purchased from American Type Culture Collection (Manassas, VA).
WM35 and 451Lu melanoma cells were provided by Dr M Herlyn
(Wistar Institute, Philadelphia, PA) and grown as described (Fang
et al., 2001). Neonatal foreskin melanocytes were isolated (Fang
et al., 2001) and cultured in phorbol 12-myristate 13-acetate-free
medium supplemented with growth supplement (Cascade Biologics,
Portland, OR).
Plasmids
BRAF expression plasmids pMCEFplink, pMCEFBRAFV600E, pEF-
BRAFV600E, and pEFplink were from Dr R Marais (Institute of
Cancer Research, London, UK) and pLXSP3-G BRAFVE:ERT2 was
from Dr M McMahon (CRI, University of California, San Francisco,
CA). LC3 cDNA plasmid was from Dr N Mizushima (Tokyo
University, Tokyo, Japan).
Antibodies
Anti-Raf-B, anti-MAPLC3 (Santa Cruz Biotech, Santa Cruz, CA), anti-
p44/42 MAPK, anti-phospho-p44/42 MAPK (Thr202/Tyr204), anti-
mTOR, anti-phospho-mTOR (Ser2448), anti-phospho-mTOR
(Ser2481), anti-Raptor, anti-Rictor, anti-phospho-AKT (Thr308),
anti-phospho-AKT(ser434), anti-AKT, anti-phospho-4E-BP1(Ser65),
antiphospho-4E-BP1(Thr37/46), anti-4E-BP1, anti-phospho-
TSC2(Thr1462), anti-TSC2 (Cell Signaling Technology, Beverly,
MA), anti-p16 (Chemicon, Temecula, CA), anti-LC3 (Novus Biolo-
gicals, Littleton, CO), anti-acetyl-histone H3 (Lys9) (Upstate,
Temecula, CA), and anti-b-actin antibodies were used. Horseradish
peroxidase-conjugated goat anti-mouse IgG and horseradish perox-
idase-conjugated donkey anti-rabbit IgG were from GE Health Care
(Piscataway, NJ), and goat anti-mouse IgG Alexa 488 was from
Molecular Probes (Carlsbad, CA).
Transfection
Transient transfection was performed using Lipofectamine Plus
(Invitrogen, Carlsbad, CA) or NHEM-Neo Nucleofector kit (Amaxa,
Gaithersburg, MD) according to the manufacturer’s instructions. For
stable clones, transfected 451Lu and SK-MEL-2 melanoma cells were
selected and maintained in G418 (1mgml1). The 451Lu ER-
BRAFV600E stable clones were established by transfecting with
pLXSP3-G BRAFVE:ERT2 plasmid, selected and maintained in
1mgml1 of puromycin. SK-MEL-2 mBRAF and 451Lu-ER-BRAF
stable cells represent a mixture of separate clones. In ER-BRAFV600E
cells, BRAF was induced by adding 4-hydroxytamoxifen (Sigma,
St Louis, MO).
shRNA plasmids and lentiviruses
BRAF knockdown was performed using human pLKO.1 lentiviral
shRNA plasmids from the RNAi Consortium collection (Open
Biosystem, Huntsville, AL). Lentiviruses were produced by transfect-
ing scrambled control or BRAF shRNA with viral packing (pSVG) and
envelope (pCMV DR8.2) plasmids into HEK293T cell lines. Super-
natants were harvested and concentrated, and viral copy number
was calculated using the quantitative reverse transcription–PCR
titration kit (Clontech, Mountain View, CA). Cells were infected with
an equal number of scrambled or BRAF viral particles and transduced
cells were selected in medium containing 1mgml1 Puromycin.
Cell proliferation, cell death, clonogenic survival, and
senescence assays
Cell growth was determined using MTT assays using 1 104 cells
plated in a 96-well plate. MTT dye (5mgml1, Sigma) was added
and viable cell number (OD540) was measured. Cells (1 105) were
cultured and on days 1, 3, and 5 were fixed in methanol and stained
with 0.5% crystal violet solution in 25% methanol. Crystal violet-
stained cells were solubilized in 0.1 M sodium citrate in 50% ethanol
and measured (OD540). The number of dead cells was measured
using the CytoTox-Glo cytotoxicity assay kit (Promega, Madison, WI)
that measures dead cell protease activity. Cells (1 104) were plated
in triplicate wells, treated with autophagy inhibitor 3-MA (Sigma),
and after 24 hours cytotoxicity assay reagent (50 ml) was added and
luminescence measured. For clonogenic assay, 5 103 cells were
cultured for 14 days, colonies were fixed, stained with 0.1% crystal
violet, washed, and the colonies were counted. For senescence-
associated-b-galactosidase-staining, cells plated in triplicate for
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72 hours were fixed, incubated with X-gal (5-bromo-4-chloro-3-
indolyl-bD-galactopyranoside) (Cell Signaling) at 37 1C overnight,
observed under a microscope for the development of blue color, and
photographed. Cells stained blue were counted and percent stained
cells were estimated.
Cell cycle and apoptosis assays
Apoptotic cells were detected using the Apo-Direct apoptosis
detection kit (Phoenix Flow System, San Diego, CA). Cells were
fixed and the DNA breaks in the cells undergoing apoptosis were
labeled with TdT and FITC-dUTP and scanned by flow cytometry.
Propidium iodide staining was performed by incubating the cells
with propidium iodide and cell cycle was analyzed by flow
cytometry.
GFP–LC3 staining
Autophagic vacuoles were identified using GFP–LC3 plasmid transfec-
tion (Kabeya et al., 2000). Cells on glass coverslips were transfected
with pEGFP-LC3 plasmid for 24 hours, fixed in paraformaldehyde,
washed, and mounted and images were captured using the Bio-Rad
Radiance 2100 MP Rainbow (Hercules, CA) confocal microscope.
Immunoblotting
Cells cultured under the indicated conditions were lysed in 1%
Triton X-100 in phosphate-buffered saline, or in RIPA buffer
containing sodium vanadate (Sigma) and a cocktail of protease
inhibitors (Roche Diagnostics, Indianapolis, IN). Protein was
estimated using the BCA protein assay kit (Pierce Biotechnology,
Rockford, IL), separated by SDS–PAGE, and transferred to a
Polyscreen membrane (Perkin Elmer Life Sciences, Boston, MA).
Membranes were blocked with 5% non-fat dry milk and incubated
overnight at 4 1C with primary antibodies. The blots were incubated
in appropriate horseradish peroxidase-conjugated secondary anti-
body and proteins were detected by chemiluminescence (Amersham
Biosciences, Piscataway, NJ). b-Actin was used as a control to
monitor protein loading variability.
Immunofluorescence and immunohistochemistry
Cells on coverslips were fixed in paraformaldehyde, permeabilized
with cold methanol, incubated with LC3 antibody (Santa Cruz), and
washed and the bound antibody was visualized using Alexa Fluor
488 (green)-conjugated secondary antibody. Nuclei were stained
with propidium iodide and images were acquired using a confocal
microscope. Immunohistochemistry was performed on sections of
formalin-fixed paraffin-embedded mouse tumors and human mela-
noma tumors using the Histostain-plus kit (Zymed, San Francisco,
CA) according to the manufacturer’s manual. Antigen retrieval was
performed by heating in a microwave for 20 minutes in citrate buffer,
pH 6.0. Endogenous peroxidase quenching was performed using 3%
H2O2. Tissue sections were incubated in primary antibody, washed
and incubated in biotinylated secondary antibody followed by
horseradish peroxidase-conjugated streptavidin and chromogen
AEC, counterstained with hematoxylin, and observed on a Nikon
phase contrast microscope (Melville, NY).
Transmission electron microscopy
Cells on coverslips were washed with phosphate-buffered saline,
fixed with 2.5% glutaraldehyde, and processed for transmission
electron microscopy. Ultrathin sections were observed and photo-
graphed using the Jeol 100 electron microscope (Tokyo, Japan) at the
UW Electron Microscope Facility.
Mouse xenograft
Athymic Ncr-nu/nu mice (4–6 weeks, male and female) were
purchased from the National Cancer Institute (NCI, Frederick,
MD). 451Lu mBRAF and vector control cells (1 106) were injected
subcutaneously into the right flanks. Tumor size was measured every
third day using digital calipers and photographed. All animal
experiments were approved by and carried out according to IACUC
guidelines.
Automated quantitative analysis
Human melanoma tissue arrays (Mini Test Array, NCI, USA)
consisting of primary lymph node and distant metastatic melanomas
and melanoma cell lines were used to quantify the expression of
BRAF, LC3, and MAP2 by AQUA as described (Warren et al., 2009).
Anti-S100 protein (Biocare Medical, Concord, CA) and Alexa Fluor
555 tagged secondary antibody was used as the melanoma tumor
mask. BRAF, LC3, and MAP2 were visualized with Alexa Fluor 647-
tagged secondary antibodies. Nuclei were stained with 4,6-
diamidino-2-phenylindole. Details of the image acquisition and
pixel quantitation analysis are described in Supplementary Data.
Statistical analysis
Data were analyzed using Prizm 4.0 (GraphPad Software, La Jolla,
CA). Mouse tumor data were analyzed using two-tailed t-test and all
other data were analyzed using one-way analysis of variance. AQUA
data were analyzed using Pearson’s correlation analysis.
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